Clinical Trial

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
Protocol Amendment History 3 changes
notable Trial sites expanded: 42 -> 48 locations 2026-05-29
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-16
notable Primary completion moved earlier: 2026-12-31 -> 2026-10-31 2026-05-16
Trial Details
NCT Number NCT07211633
Lead Sponsor TG Therapeutics, Inc.
Conditions Relapsing Multiple Sclerosis
Enrollment 360 participants
Start Date 2025-07-09
Primary Completion 2026-10-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17